HIV prevention drug priced out of reach for 90% of those that need it
For the 1.2 million Americans at high risk of contracting HIV, pre-exposure prophylaxis (PrEP) can prevent them from contracting the virus. Unfortunately, the high cost of PrEP keeps 90% of people at risk from accessing the drug. Since Gilead Sciences’ Truvada (Emtricitabine / Tenofovir), the brand name version of PrEP, was approved six years ago, its average wholesale price has increased by about 45 percent. In 2018, Gilead sold it for a whopping $2,000 for just a 30-day supply.